Previous Article | Next Article 
Infection and Immunity, December 1999, p. 6445-6453, Vol. 67, No. 12
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Interaction of Cationic Peptides with Lipoteichoic
Acid and Gram-Positive Bacteria
Monisha G.
Scott,
Michael R.
Gold, and
Robert E. W.
Hancock*
Department of Microbiology and Immunology,
University of British Columbia, Vancouver, British Columbia V6T
1Z3, Canada
Received 7 June 1999/Returned for modification 23 July
1999/Accepted 23 September 1999
 |
ABSTRACT |
Compounds with antiendotoxin properties have been extensively
studied for their potential as therapeutic agents for sepsis attributable to gram-negative bacteria. However, with the increasing incidence of gram-positive sepsis, there is interest in identifying compounds with a broad spectrum of action against both gram-positive and gram-negative bacteria. A series of synthetic
-helical cationic peptides related to bee melittin and silk moth cecropin have previously been shown to bind lipopolysaccharide (LPS) with high affinity, inhibit
LPS-induced tumor necrosis factor alpha (TNF-
) production in vitro
and in vivo, and kill gram-negative bacteria. In this study, we
analyzed whether these peptides were active against gram-positive
bacteria; whether they could bind to lipoteichoic acid (LTA), the major
proinflammatory structure on gram-positive bacteria; and whether they
could block the ability of LTA to promote the release of cytokines by
the RAW 264.7 murine macrophage cell line. We found that the cationic
peptides demonstrated moderate growth-inhibitory activity toward
gram-positive bacteria. In addition, the peptides bound LTA with high
affinity. This correlated with the ability of the peptides to block
LTA-induced production of TNF and interleukin-6 by RAW 264.7 cells but
did not correlate with their ability to kill the bacteria. The peptides
also effectively inhibited LTA-induced TNF production in a whole human
blood assay. The peptides were also able to partly block the ability of
heat-killed Staphylococcus aureus, as well as soluble
products of live S. aureus, to stimulate cytokine
production by macrophages. Our results indicate that these cationic
peptides may be useful to prevent sepsis and inflammation caused by
both gram-negative and gram-positive bacteria.
 |
INTRODUCTION |
Sepsis is associated with the
presence of pathogenic microorganisms or their toxins in the blood. It
can result from infections with either gram-negative or gram-positive
bacteria. Sepsis due to a gram-negative bacterium (gram-negative
sepsis) is usually caused by the release of a bacterial outer membrane
component, endotoxin (lipopolysaccharide [LPS]). The systemic release
of cytokines, in particular tumor necrosis factor alpha (TNF-
), can
result in septic shock and death. Gram-positive sepsis is also presumed
to be due to the release of bacterial cell wall components. A number of
gram-positive cell wall constituents, including lipoteichoic acid (LTA)
(10), peptidoglycan (PG) (16), Streptococcus rhamose-glucose polymers (24), and
Staphylococcus capsular polysaccharide (23), have
been shown to stimulate the production of inflammatory mediators in
vitro. When injected into animals, these gram-positive cell wall
components elicit many of the characteristic features of septic shock,
including cytokine production, leukocytopenia, circulatory failure,
multiple-organ dysfunction syndrome, and mortality (3, 14, 15, 18,
31). PG has also been shown to enhance the toxicity of endotoxin
in animals (26). The increasing incidence of
gram-positive-microorganism-induced septic shock (2)
indicates that there is a need to develop therapeutic strategies to
prevent the activation of inflammatory cells by components of
gram-positive cell walls.
Two of the major gram-positive cell wall components that are known to
stimulate the production of inflammatory mediators are PG and LTA. PG
is an essential constituent of the gram-positive cell wall, while LTAs
are associated with the cell walls of most, but not all, gram-positive
bacteria (6, 7). PG is a polymer of alternating GlcNAc and
MurNAc residues with tetrapeptide side chains, cross-linked in
gram-positive bacteria by short peptides. LTAs are amphipathic
compounds which typically consist of a repeating glycerol phosphate
backbone that is substituted with D-alanine, sugars such as
glucose, and a single lipid side chain that intercalates into the
cytoplasmic membrane (7). Both LTA and PG are released spontaneously into the culture medium during growth of gram-positive bacteria (25). Moreover,
-lactam antibiotics such as
penicillin enhance the release of LTA and PG (12, 29). Thus,
the release of LTA and PG from gram-positive bacteria may promote
septic shock during bacterial infections and during subsequent
antibiotic treatment.
Despite their structural differences, LTA and PG both activate
macrophages and polymorphonuclear leukocytes by binding to CD14
(4, 11, 32), a surface receptor that mediates responses to
LPS (27, 28). Thus, substances that bind to bacterial
components and ablate their ability to bind to CD14 would be good
candidates for use as anti-inflammatory agents. Compounds with a broad
spectrum of binding to both gram-positive and gram-negative bacterial
products would be extremely useful in this regard.
We and others have previously shown that cationic peptides can bind to
LPS and neutralize its ability to stimulate the production of
inflammatory cytokines (8, 22). In particular, we have focused on derivatives of an
-helical peptide that is a hybrid of
silk moth cecropin and bee melittin (1). The parent peptide, CEME, contains the N-terminal 8 amino acids of cecropin followed by the
first 18 amino acids of melittin. CEME and its derivatives have strong
antimicrobial activity against gram-negative bacteria, bind LPS with a
high affinity, block LPS-induced macrophage activation in vitro, and
block LPS-induced toxicity in mice (8, 19, 22).
In this study, we have investigated whether these synthetic cationic
peptides have antimicrobial activity toward gram-positive bacteria,
whether they can bind LTA, and whether they can block the ability of
LTA, PG, or heat-killed Staphylococcus aureus to induce the
production of inflammatory mediators by the RAW 264.7 murine macrophage
cell line. We have also tested the ability of the peptides to work in
vivo, in a whole-blood assay. Our results indicate that several of
these cationic peptides can kill gram-positive bacteria and prevent the
production of TNF-
and interleukin-6 (IL-6) in response to
heat-killed gram-positive bacteria or purified gram-positive bacterial
cell wall components. Thus, these cationic peptides may have
therapeutic potential for the treatment of gram-positive sepsis.
 |
MATERIALS AND METHODS |
Bacterial strains and growth conditions.
Bacterial strains
were grown on Meuller-Hinton medium supplemented with 1.5% (wt/vol)
agar, with the exception of Streptococcus pyogenes, which
was grown on Todd-Hewitt medium. The strains used in this study were
S. aureus RN4220, ATCC 25293, and SAP0017
(methicillin-resistant S. aureus), as well as clinical
S. aureus isolates received from A. Chow (Department of
Medicine, University of British Columbia), Staphylococcus
epidermidis (a clinical isolate from A. Chow), Streptococcus
pyogenes ATCC 19615, Enterococcus faecalis ATCC 29212, Bacillus subtilis (lab strain), Listeria
monocytogenes NCTC 7973, Cornyebacterium xerosis (lab
strain), and Escherichia coli UB1005 (20).
Bacterial products.
LTA from S. aureus,
Streptococcus pyogenes, and B. subtilis, as well
as PG peptide from the cell wall of S. aureus
(D-ala-isoglutaminyl-L-lys-D-ala-D-ala), were purchased from Sigma Chemical Co (St. Louis, Mo.). PG from Micrococcus luteus was purchased from Wako (Osaka, Japan).
LTA and PG were resuspended in endotoxin-free water (Sigma). The
Limulus amoebocyte lysate assay (Sigma) was performed on the
LTA and PG preparations to confirm that lots were not significantly
contaminated by endotoxin. The level of endotoxin contamination was
less than 1 ng/ml, a concentration that did not cause significant
cytokine production (<0.2 ng/ml) in the RAW cell assay. Heat-killed
S. aureus was prepared by boiling the bacterial cells for 10 min and then washing them three times with phosphate-buffered saline. The efficacy of the heat treatment was confirmed by culturing the
bacteria overnight to ensure that there was no growth.
Cationic peptides.
The cationic peptides were synthesized at
the University of British Columbia service facility by Fmoc
[N-(9-fluorenyl)methoxycarbonyl] chemistry
(22). The amino acid sequences of the peptides are found in
Table 1 in the single-letter amino acid
code.
Determination of MICs.
The MICs of each peptide for a range
of microorganisms were determined by the modified broth dilution method
(33). Experiments were performed with Mueller-Hinton medium
(with the exception of those involving Streptococcus
pyogenes, which required Todd-Hewitt medium) in 96-well
polypropylene microtiter plates (Costar, Cambridge, Mass.). Wells were
inoculated with 10-µl volumes containing approximately 2 × 106 to 2 × 107 CFU of the test
organism/ml. Samples of the bacterial inoculum were plated to ensure
that they were within the proper range of concentrations. The MICs were
determined after 18 h of incubation of the plates at 37°C. The
MIC was considered to be the lowest peptide concentration at which
growth was inhibited.
Determination of LTA binding affinity.
The relative binding
affinity of each peptide for LTA was determined by modifying the LPS
binding assay described previously by Moore et al. (17).
Dansyl polymyxin B (DPX) was used at a concentration of 2.5 µM to
obtain 90 to 100% of the maximum fluorescence when bound to LTA. The
DPX and 5 µg of S. aureus LTA were mixed in 1 ml of 5 mM
HEPES (pH 7.2). Fluorescence was measured by the use of a fluorescence
spectrophotometer. Sequential additions of synthetic peptide, in 5-µl
volumes, were made to the reactions mixtures, and the resulting
decreases in DPX fluorescence were determined.
Cell culture.
The murine macrophage cell line RAW 264.7 was
obtained from the American Type Culture Collection (Manassas, Va.). The
cells were maintained in Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum and passaged as described previously (13). For stimulation with bacterial products, the cells
were plated at a density of 106/well in 24-well plates,
incubated overnight to permit adherence, and then washed with fresh
medium before stimulation. The cells were stimulated with LTA, PG
peptide, or heat-killed S. aureus. To stimulate the RAW
264.7 cells with soluble products of live S. aureus, the
bacteria were grown overnight in Mueller-Hinton medium, diluted in
phosphate-buffered saline to a concentration of 107 to
108 per ml, and added to a Transwell diffusion chamber
(Costar) in which a 0.2-µm-pore-size membrane separated the bacteria
from the RAW 264.7 cells. In all cases, the supernatants of the RAW 264.7 culture were collected and used for cytokine enzyme-linked immunosorbent assays (ELISAs).
Whole-blood assay.
Blood from three donors was collected by
venipuncture into tubes (Becton Dickinson, Franklin Lakes, N.J.)
containing 14.3 USP units of heparin/ml of blood. Whole blood was
stimulated with a 1-µg/ml solution of S. aureus LTA in the
presence or absence of peptide (50 µg/ml) in polypropylene tubes at
37°C for 6 h. The samples were centrifuged for 10 min at
2,000 × g, and the plasma was stored at
20°C until
analyzed by ELISA.
Cytokine assays.
The concentrations of TNF-
and IL-6 in
the RAW 264.7 supernatants were determined by ELISA (Endogen, Hornby,
Ontario, Canada) in accordance with the manufacturer's suggestions.
The concentration of TNF in serum was determined by ELISA (R&D Systems,
Minneapolis, Minn.).
 |
RESULTS |
Antimicrobial activity of the peptides.
CEME is an synthetic
-helical cationic peptide which contains the N-terminal 8 amino
acids of silk moth cecropin followed by the first 18 amino acids of bee
melittin (Table 1). CEME and some of its derivatives have previously
been shown to have strong antimicrobial activity against a broad range
of gram-negative bacteria (22). In this study, we asked
whether CEME and/or its derivatives were capable of killing a variety
of gram-positive bacteria, including clinically relevant pathogens. The
peptides tested included CEME, a variant of CEME that is modified at
the C terminus (CEMA), and two amphipathic derivatives of CEME (CP26 and CP29), as well as six other peptide variants with sequences related
to CEME (Table 1). We have previously shown that all of these peptides,
with the exception of CP208, are potent inhibitors of gram-negative
bacterial growth (22). The MICs of these peptides for
E. coli ranged from 0.5 to 2 µg/ml, with the exception of CP208, which had an MIC of 32 µg/ml. In contrast to their strong activity against E. coli, we found that the antimicrobial
activity of the peptides toward gram-positive bacteria differed widely depending on the bacterium (Table 2). In
general, most of the CEME-related cationic peptides, with the exception
of CP208, had good activity against C. xerosis and L. monocytogenes, while many of the peptides had good activity
against Streptococcus pyogenes, S. epidermidis,
and a variety of S. aureus lab strains and clinical isolates. Note that the MICs of peptides that did have significant antimicrobial activity were often in the range of 4 to 16 µg/ml, which is considerably higher than their MICs for E. coli,
which ranged from 0.5 to 2 µg/ml. Nevertheless, several of the
CEME-related peptides had significant antimicrobial activity against
multiple gram-positive bacteria.
Of the cationic peptides tested, CEME had the lowest MICs for the
gram-positive bacteria that were tested, while CEMA and CP203 were only
slightly less effective. CM7 also had significant antimicrobial
activity against gram-positive bacteria, although it was less effective
than CEME, CEMA, or CP203. CM7 was also the only peptide that had
significant activity against E. faecalis. Despite being
highly effective against gram-negative bacteria, CP29, CP207, and
CP
2 had only modest antimicrobial activity against most of the
gram-positive bacteria, while CP26 and CP208 had little activity. Note
that all of the cationic peptides with the exception of CP208 were
highly active against C. xerosis. Thus, some of these
CEME-related cationic peptides have significant activity against a
broad range of gram-positive and gram-negative bacteria while others
are active only against gram-negative bacteria and C. xerosis.
In addition to testing CEME-like peptides, we also asked whether the
cationic lipopeptide polymyxin B displayed antimicrobial activity
toward gram-positive bacteria (Table 2). Polymyxin B is generally
considered to be a gram-negative-selective drug which has very low MICs
(0.1 to 2 µg/ml) for gram-negative bacteria such as E. coli. We found that while polymyxin B had good antimicrobial activity toward C. xerosis and L. monocytogenes
as well as modest activity toward Streptococcus pyogenes, it
had minimal antimicrobial activity against other gram-positive
bacteria. Thus, while polymyxin B has antimicrobial activity toward
some species of gram-positive bacteria, it does not have as broad a
range as CEME and some of its derivatives, such as CEMA and CP203.
Binding of CEME-related peptides to S. aureus LTA.
CEME-related cationic peptides have been shown to bind to purified
E. coli LPS in vitro (22). The ability of the
peptides to bind LPS is likely to play a significant role in their
ability to neutralize LPS that is shed from bacteria and thereby
prevent inflammatory responses. Since LTA has some structural analogy (being anionic and acylated) to LPS, we asked whether the CEME-related peptides could bind to purified LTA in vitro. To do this, we modified the DPX fluorescence assay that we had previously used to monitor the
binding of these peptides to LPS. When excited at 340 nm, DPX
fluoresces at 485 nm. This fluorescence is increased when DPX binds to
LPS and is reduced when CEME-related peptides bind to LPS and displace
the DPX. Since we observed a similar increase in DPX fluorescence when
LTA was added, we were able to perform an analogous displacement assay
to determine whether the CEME-related peptides could bind to purified LTA.
Figure 1 shows that the CEME-related
peptides were able to displace up to 90% of the bound DPX from
purified LTA. In previous studies, we found that these peptides
displaced only about 50% of the DPX from E. coli O111:B4
LPS (17, 22). Most of the peptides had a higher affinity for
LTA than polymyxin B, with CM5 and CEME being exceptions. The abilities
of the peptides to bind LTA did not correspond with their MICs for
gram-positive bacteria (Table 2), since CEME was the most effective
peptide of this series against gram-positive bacteria but had a
relatively low affinity for S. aureus LTA compared to some
of the other peptides. Conversely, CP207 had the highest affinity for
purified LTA, but its MICs for gram-positive bacteria were in general
fourfold higher than those of CEME. Furthermore, CP208 also exhibited
good affinity for purified LTA, even though it was unable to kill
gram-positive bacteria. These results indicate that the ability to bind
LTA is probably not the major mechanism by which CEME-related peptides kill gram-positive bacteria. The exact mechanism by which cationic peptides kill bacteria is not known. Nevertheless, the ability of these
peptides to bind LTA could prevent LTA that is shed by bacteria from
inducing inflammatory responses. To test this hypothesis, we asked
whether the CEME-related peptides could block the ability of soluble
LTA to induce the production of inflammatory cytokines by macrophages.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 1.
Binding affinities of the peptides for S. aureus LTA as measured by the DPX displacement assay. Purified
soluble S. aureus LTA (5 µg/ml) was incubated with 2.5 µM DPX, and the fluorescence at 485 nm was measured. Peptides were
added in increments of 5 µg/ml, and the DPX fluorescence was measured
after each addition. Each data point represents the mean of values from
three independent experiments. The standard errors of the means were
all less than 10%. PB, polymyxin B.
|
|
CEME-related peptides inhibit LTA-induced cytokine secretion.
Previous studies have demonstrated that LTA results in many of the
characteristics of septic shock when injected into animals (3, 14,
15, 18, 31). Consistent with this observation, LTA also induces
the production of inflammatory cytokines by macrophages in vitro
(10). Therefore, we asked whether the cationic peptides could block LTA-induced cytokine production by the murine macrophage cell line RAW 264.7. Figure 2 shows that
LTA stimulated the release of TNF-
and IL-6 by RAW 264.7 cells.
Maximal TNF-
and IL-6 production was observed after 6 h, and
0.1 µg/ml was the minimal concentration of S. aureus LTA
that induced significant cytokine production. CEMA (20 µg/ml)
significantly blocked cytokine production elicited by LTA at 0.1 µg/ml (Table 3) or 1 µg/ml (Fig.
3). When the cells were stimulated with
LTA at 10 µg/ml, CEMA was not as effective, resulting in only
approximately 50% inhibition. The production of TNF-
and IL-6 in
response to stimulation at 1 µg/ml (Fig. 3) was completely suppressed
over the entire 24-h observation period by 20-µg/ml CEMA (data not
shown). Figure 4 shows that a 10-µg/ml
concentration of CEMA was sufficient to cause nearly complete
inhibition of production of TNF-
and IL-6 by RAW 264.7 cells
stimulated with LTA at 1 µg/ml. The PG peptide and M. luteus PG were also tested for their ability to induce the
production of TNF and IL-6 by RAW 264.7 cells. Addition of these
substances at concentrations of 100 ng to 10 µg/ml did not result in
significant levels of TNF and IL-6 (data not shown), and so peptide
inhibition experiments were not performed. Nevertheless, our results
show that CEMA is a potent inhibitor of LTA-induced production of
inflammatory cytokines.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 2.
Production of TNF- ( ) and IL-6 ( ) by RAW 264.7 cells incubated for 6 h with the indicated doses of S. aureus LTA in the absence (solid line) or presence (broken line)
of 20 µg of CEMA. TNF- and IL-6 concentrations in the cell
supernatant were determined by ELISA. The levels of TNF- and IL-6
produced by macrophages incubated in medium alone for 6 h were
less than 0.3 ng/ml. The experiment was repeated three times with
similar results, and the data from one representative experiment are
shown.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 3.
Production of TNF-
( ) and
IL-6 ( ) by RAW 264.7 cells stimulated with S. aureus LTA
at 1 µg/ml or E. coli O111:B4 LPS at 100 ng/ml ( [TNF- production]) for 1 to 6 h in the absence (solid line)
or presence (broken line) of 20 µg of CEMA. Supernatant was removed
at each time point and assayed for cytokine levels. The experiment was
repeated three times with similar results, and the data from one
representative experiment are shown.
|
|

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 4.
Production of TNF- (solid lines) and IL-6 (dotted
lines) by RAW 264.7 cells stimulated with S. aureus LTA at 1 µg/ml and with increasing doses of CEMA. The experiment was repeated
three times with similar results, and the data from one representative
experiment are shown.
|
|
Having shown that the CEMA peptide can block the ability of S. aureus LTA to stimulate TNF-
and IL-6 production by RAW 264.7 cells, we wished to extend these results and determine whether the
other CEME-related peptides could block LTA-stimulated cytokine production. In addition to testing their ability to block cytokine production stimulated by S. aureus LTA at either 100 ng/ml
or 1 µg/ml (Table 3), we also tested the peptides for their ability to block cytokine production induced by LTAs from B. subtilis and Streptococcus pyogenes (Table 3). In this
way, we could determine whether some or all of the peptides had the
ability to neutralize LTAs from a broad spectrum of gram-positive
bacteria. As a control, we used 10 to 100 mM phorbol 12-myristate
13-acetate (PMA; Sigma) to stimulate the cells and found that the
peptides did not block cytokine production (~0.6 ng/ml) caused by PMA
(data not shown). We found that almost all of the CEME-related peptides
were very potent inhibitors of LTA-stimulated TNF-
and IL-6
production. The exceptions were CP26 and CP208, which caused only
partial inhibition of cytokine production. These two peptides also have little or no antimicrobial activity toward gram-positive bacteria. Nevertheless, many of the CEME-related peptides were potent antagonists of LTAs from a broad spectrum of gram-positive bacteria. Thus, these
peptides not only have antimicrobial activity against both gram-negative and gram-positive bacteria but also block the ability of
the major cell wall components released from these bacteria (LPS and
LTA) to stimulate inflammatory responses.
Effect of cationic peptides on RAW 264.7 cell production of TNF and
IL-6 in response to S. aureus.
We next examined whether the
CEME-related peptides could block the induction of TNF-
and IL-6
production by intact heat-killed S. aureus or by soluble
products of S. aureus. These stimuli may better reflect a
physiological encounter between macrophages and bacteria than the
addition of purified LTA to cultures. Incubating RAW 264.7 cells with
intact heat-killed S. aureus for 6 h resulted in
secretion of very high levels of TNF-
(approximately 20 ng/ml). When
RAW 264.7 cells were exposed to soluble products of live S. aureus by culturing the macrophages and the bacteria in separate compartments of Transwell dishes, the macrophages also produced significant amounts of TNF-
(approximately 2.2 ng/ml). Neither the
intact heat-killed S. aureus nor the soluble products of
S. aureus caused significant (above that evident with medium
alone) production of IL-6. At a concentration of 50 µg/ml (found
optimal from a dose-response curve [data not shown]), a number of the CEME-related peptides significantly decreased the ability of the intact
heat-killed S. aureus and the S. aureus soluble
products to stimulate TNF-
production (Fig.
5). The CEMA, CM7, CP
2, CP29, and
CP203 peptides were the most effective at inhibiting S. aureus-stimulated TNF-
production, decreasing the level of
TNF-
secretion by more than 50%. Interestingly, the CEME peptide
itself was somewhat less effective at blocking S. aureus-stimulated TNF-
production, even though it had the
lowest MICs for S. aureus of all the peptides. Nevertheless,
many of the CEME-related peptides were able to reduce the ability of
S. aureus or its products to cause TNF-
release.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 5.
RAW 264.7 cells were incubated with boiled S. aureus (solid bars) or live S. aureus separated from
the RAW 264.7 cells by a filter (open bar) for 6 h. The
supernatant was collected and measured for TNF- by ELISA. The data
are presented as percent inhibition of cytokine production ± the
standard error of the mean for triplicate samples. PB, polymyxin B.
|
|
Effect of cationic peptides on whole-blood stimulation by LTA.
Although CEMA and CEME were shown to be effective in a mouse model of
endotoxic shock (22), it was of interest to determine the
effectiveness of the peptides against LTA in a more realistic model.
They were tested in an ex vivo assay in which LTA and peptide were
added to blood samples from human volunteers and, after incubation of
the blood specimens for 6 h, the sera were separated and tested for TNF levels by ELISA. It was found that the peptides effectively inhibited LTA-induced TNF production (Fig.
6), although not quite as well as in the
RAW cell assay. CP29 was the most effective peptide, inhibiting TNF
production by 83%, whereas CP26, CP208, and CP
2 were relatively
ineffective. Therefore, the peptides were effective at reducing
LTA-induced stimulation of TNF both in vitro and in human blood.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 6.
Production of TNF- by whole blood stimulated with
E. coli O111:B4 LPS at 100 ng/ml or S. aureus LTA
at 1 µg/ml and/or peptide at 50 µg/ml was measured by ELISA after a
6-h incubation. The three different types of bar represent the three
donors. The numbers above the bars represent the average amounts of TNF
inhibition by the peptides ± standard errors. PB, polymyxin B.
|
|
 |
DISCUSSION |
In this study, CEME-related cationic peptides were tested for
their ability to kill gram-positive bacteria, their ability to bind
LTA, and their ability to neutralize cytokine production by macrophages
stimulated with products of gram-positive bacteria. Many of the
peptides had activity against gram-positive bacteria, although a few
peptides had no antimicrobial activity. All of the peptides were able
to bind LTA, and many were able block the production of cytokines by
macrophages stimulated with different species of LTA. The CEME-related
peptides were also effective in blocking cytokine production by RAW
264.7 cells stimulated with heat-killed S. aureus.
It was of interest to determine if the peptides have potential
therapeutic value for the treatment of gram-positive sepsis as they
have shown for treatment of gram-negative sepsis. Although the peptides
had better antimicrobial activity against gram-negative bacteria, some
of the peptides were still active against gram-positive bacteria. It is
likely that structural differences among these peptides determine
whether they can interact with surface structures of various
gram-positive and gram-negative bacteria. The different abilities of
the various CEME-related peptides to kill gram-positive bacteria may
point to structural features that are important for this process. CP26
and CP29 were designed to be more amphipathic than CEME, a property
which might help them intercalate into membranes. Although CP29 still
had reasonable antimicrobial activity toward gram-positive bacteria, it
was less effective than CEME. CP26, while being very effective against
E. coli, had no antimicrobial activity toward gram-positive
bacteria. Thus, an amphipathic nature, by itself, is not sufficient for
these cationic peptides to kill gram-positive bacteria. Except for
three conservative amino acid changes, the major difference between
CP26 and CP29 is that the C terminus of CP29 is identical to that of
CEME (PALIS [single-letter code]) while the C terminus of CP26
consists of PLISS. Consistent with the idea that the C-terminal PALIS
sequence confers greater activity toward gram-positive bacteria, CP203,
which also has a C-terminal PALIS sequence, was somewhat more potent
than CP207, which has a C-terminal PLISS sequence. Despite having the
same C-terminal PLISS sequence as CP26, CP207 had modest activity
against gram-positive bacteria while CP26 did not. These two peptides differ only at 2 amino acids, at positions 12 and 13, where CP207 has a
valine and a leucine whereas CP26 has two alanine residues. The
presence of the larger hydrophobic side chains at residues 12 and 13 in
CP207 may therefore be important for activity against gram-positive
bacteria. Both CEME and CEMA have an alanine and a valine at positions
12 and 13, suggesting that one larger side chain may be sufficient.
CP203, while having a PALIS sequence at the C terminus, has alanine
residues at positions 12 and 13. Thus, the CEME-like peptides that have
the highest antimicrobial activity against gram-positive bacteria have
a C-terminal PALIS sequence and valines or leucines instead of alanines
at positions 12 and 13.
A hydrophobic residue at position 2 appears to be important for a
CEME-like peptide to have antimicrobial activity against gram-positive
and gram-negative bacteria. CP208, which has a lysine at position 2, had no antimicrobial activity against either gram-positive or
gram-negative bacteria. A tryptophan at position 2 appears to be
optimal for antimicrobial activity. CM5, which has a leucine at this
position, has little activity toward gram-positive bacteria and reduced
activity toward E. coli. CM7 also has a leucine at position
2, but changes elsewhere, including a tryptophan at position 3, in the
peptide may compensate for this to some extent since CM7 has modest
activity against gram-positive bacteria and good activity toward
gram-negative bacteria.
Although the mechanism of action of these CEME-related peptides against
gram-positive bacteria is not clearly understood, it does not appear to
be related to their ability to bind LTA, since the relative abilities
of these peptides to bind LTA did not correspond to their MICs. Even
though many of the peptides had a higher affinity for S. aureus LTA than did CEME, it was the most effective of the
peptides at killing S. aureus and other gram-positive
bacteria. While the ability of the peptides to bind LTA may not be
important for their antimicrobial activity, it is likely to be
important for reducing the ability of shed LTA to stimulate
inflammatory reactions.
LTA, at high doses, has been shown to stimulate the production of
cytokines by the murine macrophage cell line RAW 264.7 (9). In this report, we have shown that the CEME-related peptides are able
to significantly inhibit the production of TNF-
and IL-6 by RAW
264.7 cells. Moreover, the peptides were able to block cytokine
production induced by LTAs from different species of gram-positive
bacteria. The abilities of the peptides to reduce the production of
TNF-
and IL-6 by LTA-stimulated RAW 264.7 cells corresponded
somewhat to their MICs. For example, CP26, which has virtually no
activity against gram-positive bacteria, was relatively ineffective at
reducing macrophage activation by LTA. On the other hand, CP26 has much
lower MICs against gram-negative bacteria and is also much more
effective at inhibiting cytokine production in response to LPS.
Similarly, CP208 had no antimicrobial activity against gram-positive
bacteria and also did not block LTA-induced cytokine production.
Moreover, the peptides that were more active against S. aureus than they were against B. subtilis were slightly
less effective at inhibiting cytokine production by macrophages
stimulated with B. subtilis LTA as opposed to S. aureus LTA. The peptides were also effective at reducing the
production of TNF in human blood in response to LTA. It was not
surprising that the levels of inhibition were lower than those evident
in the RAW cell system, since blood has many factors which might inhibit the peptides. Polymyxin B was found to inhibit LTA-induced cytokine production, partly in contrast to the findings of other researchers (5, 31). This could be due to the concentrations of polymyxin B used in this study (20 to 50 µg/ml), which were much
higher than those used previously (5 to 10 µg/ml). It is reasonable
to assume that LTA and polymyxin B could interact, as suggested by the
DPX assay, based on the negatively charged lipid structure of LTA and
the cationic structure of polymyxin B. Since LTA, like LPS, has both a
polyanionic and a lipidic nature, it seems reasonable that it should be
able to interact with polymyxin B and DPX, although the kinetics of
binding of DPX to LTA suggested a lower affinity than that observed for
DPX-LPS binding. We have previously found that some antibiotics and
other peptides with no charge do not work in the DPX assay. The PG
preparations tested were not effective in stimulating macrophages to
produce TNF and IL-6; therefore, no conclusions can be drawn with
regard to the effectiveness of the peptides in PG-induced cell
stimulation. In other studies, PG has been used in conjunction with LTA
to cause sepsis-like conditions in animals (3). This most
likely mimics a physiological situation in which PG attached to LTA is released from gram-positive bacteria.
The results of this study demonstrate that the CEME-related
-helical
peptides tested are not only effective against gram-negative sepsis but
also may have therapeutic value in the treatment of gram-positive
sepsis. These cecropin-melittin hybrids have demonstrated a broad range
of activities, including antibacterial activity, antiendotoxin
activity, the ability to synergize with other antibiotics, and efficacy
in animal models of infection (22). Although there have been
many new therapies for gram-negative sepsis examined in recent years
(21, 30), very little progress has been achieved in finding
new therapies for gram-positive sepsis. In this report, we have shown
that CEME-related peptides can kill gram-positive bacteria, bind LTA
released from gram-positive bacteria, and block cytokine release by
macrophages stimulated with gram-positive bacteria or their products.
The effects of the peptides on soluble LTA are significant, since LTA
is released by bacteria during normal growth and LTA release is
enhanced by
-lactam antibiotics. Although the CEME-related peptides
lack the potency of some antibiotics, they are able to bind bacterial
products released by gram-positive bacteria and significantly reduce
macrophage activation. Thus, CEME-related peptides may be an important
tool for the prevention of gram-positive sepsis, by themselves or in
concert with other antibiotics.
 |
ACKNOWLEDGMENTS |
This research was funded by grants from the Canadian Bacterial
Diseases Network (to R.E.W.H.) and from the Medical Research Council
(MRC) of Canada to M.R.G. M.G.S. was supported by a studentship from the MRC. M.R.G. is the recipient of an MRC scholarship, and R.E.W.H. is the recipient of an MRC Distinguished Scientist Award.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, University of British Columbia, 6174 University Blvd., Vancouver, British Columbia V6T 1Z3, Canada. Phone:
(604) 822-2682. Fax: (604) 822-6041. E-mail:
bob{at}cmdr.ubc.ca.
Editor:
J. R. McGhee
 |
REFERENCES |
| 1.
|
Boman, H. G.,
D. Wade,
I. A. Boman,
B. Wahlin, and R. B. Merrifield.
1989.
Antibacterial and antimalarial properties of peptides that are cecropin-melittin hybrids.
FEBS Lett.
259:103-106[Medline].
|
| 2.
|
Bone, R. C.
1994.
Gram-positive organisms and sepsis.
Arch. Intern. Med.
154:26-34[Abstract].
|
| 3.
|
De Kimpe, S. J.,
M. Kengatharan,
C. Thiemermann, and J. R. Vane.
1995.
The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure.
Proc. Natl. Acad. Sci. USA
92:10359-10363[Abstract/Free Full Text].
|
| 4.
|
Dziarski, R.,
R. I. Tapping, and P. S. Tobias.
1998.
Binding of bacterial peptidoglycan to CD14.
J. Biol. Chem.
273:8680-8690[Abstract/Free Full Text].
|
| 5.
|
English, B. K.,
C. C. Patrick,
S. L. Orlicek,
R. McCordic, and J. L. Shenep.
1996.
Lipoteichoic acid from viridans streptococci induces the production of tumor necrosis factor and nitric oxide by murine macrophages.
J. Infect. Dis.
174:1348-1351[Medline].
|
| 6.
|
Fischer, W.
1988.
Physiology of lipoteichoic acids in bacteria.
Adv. Microb. Physiol.
29:233-302[Medline].
|
| 7.
|
Fischer, W.,
T. Mannsfeld, and G. Hagen.
1990.
On the basic structure of poly(glycerophosphate) lipoteichoic acids.
Biochem. Cell Biol.
68:33-43[Medline].
|
| 8.
|
Gough, M.,
R. E. W. Hancock, and N. M. Kelly.
1996.
Antiendotoxin activity of cationic peptide antimicrobial agents.
Infect. Immun.
64:4922-4927[Abstract].
|
| 9.
|
Grunfeld, C.,
M. Marshall,
J. K. Shigenaga,
A. H. Moser,
P. Tobias, and K. R. Feingold.
1999.
Lipoproteins inhibit macrophage activation by lipoteichoic acid.
J. Lipid Res.
40:245-252[Abstract/Free Full Text].
|
| 10.
|
Heumann, D.,
C. Barras,
A. Severin,
M. P. Glauser, and A. Tomasz.
1994.
Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes.
Infect. Immun.
62:2715-2721[Abstract/Free Full Text].
|
| 11.
|
Heumann, D.,
M. P. Glauser, and T. Calandra.
1998.
Molecular basis of host-pathogen interaction in septic shock.
Curr. Opin. Microbiol.
1:49-55.
[Medline] |
| 12.
|
Horne, D., and A. Tomasz.
1979.
Release of lipoteichoic acid from Streptococcus sanguis: stimulation of release during penicillin treatment.
J. Bacteriol.
137:1180-1184[Abstract/Free Full Text].
|
| 13.
|
Kelly, N. M.,
L. Young, and A. S. Cross.
1991.
Differential induction of tumor necrosis factor by bacteria expressing rough and smooth lipopolysaccharide phenotypes.
Infect. Immun.
59:4491-4496[Abstract/Free Full Text].
|
| 14.
|
Kengatharan, K. M.,
S. De Kimpe,
C. Robson,
S. J. Foster, and C. Thiermermann.
1998.
Mechanism of gram-positive shock: identification of peptidoglycan and lipoteichoic acid moieties essential in the induction of nitric oxide synthase, shock, and multiple organ failure.
J. Exp. Med.
188:305-315[Abstract/Free Full Text].
|
| 15.
|
Le Roy, D.,
P. Morand,
S. Lengacher,
M. Celio,
G. E. Grau,
M. P. Glauser, and D. Heumann.
1996.
Streptococcus mitis cell walls and lipopolysaccharide induce lethality in D-galactosamine-sensitized mice by a tumor necrosis factor-dependent pathway.
Infect. Immun.
64:1846-1849[Abstract].
|
| 16.
|
Mattsson, E.,
J. Rollof,
J. Verhoef,
H. Van Dijk, and A. Fleer.
1994.
Serum-induced potentiation of tumor necrosis factor alpha production by human monocytes in response to staphylococcal peptidoglycan: involvement of different serum factors.
Infect. Immun.
62:3837-3843[Abstract/Free Full Text].
|
| 17.
|
Moore, R. A.,
N. C. Bates, and R. E. W. Hancock.
1986.
Interaction of polycationic antibiotics with Pseudomonas aeruginosa lipopolysaccharide and lipid A studied by using dansyl-polymyxin.
Antimicrob. Agents Chemother.
29:496-500[Abstract/Free Full Text].
|
| 18.
|
Natanson, C.,
R. L. Danner,
R. J. Elin,
J. M. Hosseini,
K. W. Peart,
S. M. Banks,
T. J. MacVittie,
R. I. Walker, and J. E. Parrillo.
1989.
Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock.
J. Clin. Investig.
83:243-251. (Erratum, 83:1087.)
|
| 19.
|
Piers, K. L.,
M. H. Brown, and R. E. W. Hancock.
1994.
Improvement of outer membrane-permeabilizing and lipopolysaccharide-binding activities of an antimicrobial cationic peptide by C-terminal modification.
Antimicrob. Agents Chemother.
38:2311-2316[Abstract/Free Full Text].
|
| 20.
|
Rocque, W. J.,
S. W. Fesik,
A. Haug, and E. J. McGroarty.
1988.
Polycation binding to isolated lipopolysaccharide from antibiotic-hypersusceptible mutant strains of Escherichia coli.
Antimicrob. Agents Chemother.
32:308-313[Abstract/Free Full Text].
|
| 21.
|
Rogy, M. A.,
L. L. Moldawer,
H. S. Oldenburg,
W. A. Thompson,
W. J. Montegut,
S. A. Stackpole,
A. Kumar,
M. A. Palladino,
M. N. Marra, and S. F. Lowry.
1994.
Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI.
Ann. Surg.
220:77-85[Medline].
|
| 22.
|
Scott, M. G.,
H. Yan, and R. E. W. Hancock.
1999.
Biological properties of structurally related -helical cationic antimicrobial peptides.
Infect. Immun.
67:2005-2009[Abstract/Free Full Text].
|
| 23.
|
Soell, M.,
M. Diab,
G. Haan-Archipoff,
A. Beretz,
C. Herbelin,
B. Poutrel, and J.-P. Klein.
1995.
Capsular polysaccharide types 5 and 8 of Staphylococcus aureus bind specifically to human epithelial (KB) cells, endothelial cells, and monocytes and induce release of cytokines.
Infect. Immun.
63:1380-1386[Abstract].
|
| 24.
|
Soell, M.,
E. Lett,
F. Holveck,
M. Scholler,
D. Wachsmann, and J.-P. Klein.
1995.
Activation of human monocytes by streptococcal rhamnose glucose polymers is mediated by CD14 antigen, and mannan binding protein inhibits TNF- release.
J. Immunol.
154:851-860[Abstract].
|
| 25.
|
Soto, A.,
T. J. Evans, and J. Cohen.
1996.
Proinflammatory cytokine production by human peripheral blood mononuclear cells stimulated with cell-free supernatants of viridans streptococci.
Cytokine
8:300-304[Medline].
|
| 26.
|
Takada, H.,
Y. Kawabata,
S. Kawata, and S. Kusomoto.
1996.
Structural characteristics of peptidoglycan fragments required to prime mice for induction of anaphylactoid reactions by lipopolysaccharides.
Infect. Immun.
64:657-659[Abstract].
|
| 27.
|
Ulevitch, R. J., and P. S. Tobias.
1995.
Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin.
Annu. Rev. Immunol.
13:437-457[Medline].
|
| 28.
|
Ulevitch, R. J., and P. S. Tobias.
1999.
Recognition of gram-negative bacteria and endotoxin by the innate immune system.
Curr. Opin. Immunol.
11:19-22[Medline].
|
| 29.
|
van Langevelde, P.,
J. T. van Dissel,
E. Ravensbergen,
B. J. Appelmelk,
I. A. Schrijver, and P. H. P. Groeneveld.
1998.
Antibiotic-induced release of lipoteichoic acid and peptidoglycan from Staphylococcus aureus: quantitative measurements and biological reactivities.
Antimicrob. Agents Chemother.
42:3073-3078[Abstract/Free Full Text].
|
| 30.
|
Van Zee, K. J.,
L. L. Moldawer,
H. S. Oldenburg,
W. A. Thompson,
S. A. Stackpole,
W. J. Montegut,
M. A. Rogy,
C. Meschter,
H. Gallati,
C. D. Schiller,
W. F. Richter,
H. Loetscher,
A. Ashkenazi,
S. M. Chamow,
F. Wurm,
S. E. Calvano,
S. F. Lowry, and W. Lesslauer.
1996.
Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081.
J. Immunol.
156:2221-2230[Abstract].
|
| 31.
|
Wakabayashi, G.,
J. A. Gelfand,
W. K. Jung,
R. J. Connolly,
J. F. Burke, and C. A. Dinarello.
1991.
Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli.
J. Clin. Investig.
87:1925-1935.
|
| 32.
|
Weidemann, B.,
J. Schletter,
R. Dziarski,
S. Kusumoto,
F. Stelter,
E. T. Rietschel,
H.-D. Flad, and A. J. Ulmer.
1997.
Specific binding of soluble peptidoglycan and muramyldipeptide to CD14 on human monocytes.
Infect. Immun.
65:858-864[Abstract].
|
| 33.
|
Wu, M., and R. E. W. Hancock.
1999.
Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane.
J. Biol. Chem.
274:29-35[Abstract/Free Full Text].
|
Infection and Immunity, December 1999, p. 6445-6453, Vol. 67, No. 12
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Zorko, M., Jerala, R.
(2008). Alexidine and chlorhexidine bind to lipopolysaccharide and lipoteichoic acid and prevent cell activation by antibiotics. J Antimicrob Chemother
62: 730-737
[Abstract]
[Full Text]
-
Meehl, M., Herbert, S., Gotz, F., Cheung, A.
(2007). Interaction of the GraRS Two-Component System with the VraFG ABC Transporter To Support Vancomycin-Intermediate Resistance in Staphylococcus aureus. Antimicrob. Agents Chemother.
51: 2679-2689
[Abstract]
[Full Text]
-
Bucki, R., Janmey, P. A.
(2006). Interaction of the Gelsolin-Derived Antibacterial PBP 10 Peptide with Lipid Bilayers and Cell Membranes.. Antimicrob. Agents Chemother.
50: 2932-2940
[Abstract]
[Full Text]
-
Motzkus, D., Schulz-Maronde, S., Heitland, A., Schulz, A., Forssmann, W.-G., Jubner, M., Maronde, E.
(2006). The novel {beta}-defensin DEFB123 prevents lipopolysaccharide-mediated effects in vitro and in vivo. FASEB J.
20: 1701-1702
[Abstract]
[Full Text]
-
Balakrishna, R., Wood, S. J., Nguyen, T. B., Miller, K. A., Suresh Kumar, E. V. K., Datta, A., David, S. A.
(2006). Structural Correlates of Antibacterial and Membrane-Permeabilizing Activities in Acylpolyamines. Antimicrob. Agents Chemother.
50: 852-861
[Abstract]
[Full Text]
-
Bowdish, D. M.E., Hancock, R. E.W.
(2005). Anti-endotoxin properties of cationic host defence peptides and proteins. Innate Immunity
11: 230-236
[Abstract]
-
Ouhara, K., Komatsuzawa, H., Yamada, S., Shiba, H., Fujiwara, T., Ohara, M., Sayama, K., Hashimoto, K., Kurihara, H., Sugai, M.
(2005). Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, {beta}-defensins and LL37, produced by human epithelial cells. J Antimicrob Chemother
55: 888-896
[Abstract]
[Full Text]
-
McMichael, J. W., Roghanian, A., Jiang, L., Ramage, R., Sallenave, J.-M.
(2005). The Antimicrobial Antiproteinase Elafin Binds to Lipopolysaccharide and Modulates Macrophage Responses. Am. J. Respir. Cell Mol. Bio.
32: 443-452
[Abstract]
[Full Text]
-
Bowdish, D. M. E., Davidson, D. J., Lau, Y. E., Lee, K., Scott, M. G., Hancock, R. E. W.
(2005). Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol.
77: 451-459
[Abstract]
[Full Text]
-
Vadyvaloo, V., Arous, S., Gravesen, A., Hechard, Y., Chauhan-Haubrock, R., Hastings, J. W., Rautenbach, M.
(2004). Cell-surface alterations in class IIa bacteriocin-resistant Listeria monocytogenes strains. Microbiology
150: 3025-3033
[Abstract]
[Full Text]
-
Fischer, H. P., Brunner, N. A., Wieland, B., Paquette, J., Macko, L., Ziegelbauer, K., Freiberg, C.
(2004). Identification of Antibiotic Stress-Inducible Promoters: A Systematic Approach to Novel Pathway-Specific Reporter Assays for Antibacterial Drug Discovery. Genome Res
14: 90-98
[Abstract]
[Full Text]
-
Neuhaus, F. C., Baddiley, J.
(2003). A Continuum of Anionic Charge: Structures and Functions of D-Alanyl-Teichoic Acids in Gram-Positive Bacteria. Microbiol. Mol. Biol. Rev.
67: 686-723
[Abstract]
[Full Text]
-
Levy, O., Jean-Jacques, R. M., Cywes, C., Sisson, R. B., Zarember, K. A., Godowski, P. J., Christianson, J. L., Guttormsen, H.-K., Carroll, M. C., Nicholson-Weller, A., Wessels, M. R.
(2003). Critical Role of the Complement System in Group B Streptococcus-Induced Tumor Necrosis Factor Alpha Release. Infect. Immun.
71: 6344-6353
[Abstract]
[Full Text]
-
Van Amersfoort, E. S., Van Berkel, T. J. C., Kuiper, J.
(2003). Receptors, Mediators, and Mechanisms Involved in Bacterial Sepsis and Septic Shock. Clin. Microbiol. Rev.
16: 379-414
[Abstract]
[Full Text]
-
Midorikawa, K., Ouhara, K., Komatsuzawa, H., Kawai, T., Yamada, S., Fujiwara, T., Yamazaki, K., Sayama, K., Taubman, M. A., Kurihara, H., Hashimoto, K., Sugai, M.
(2003). Staphylococcus aureus Susceptibility to Innate Antimicrobial Peptides, {beta}-Defensins and CAP18, Expressed by Human Keratinocytes. Infect. Immun.
71: 3730-3739
[Abstract]
[Full Text]
-
Scott, M. G., Davidson, D. J., Gold, M. R., Bowdish, D., Hancock, R. E. W.
(2002). The Human Antimicrobial Peptide LL-37 Is a Multifunctional Modulator of Innate Immune Responses. J. Immunol.
169: 3883-3891
[Abstract]
[Full Text]
-
Plitnick, L. M., Jordan, R. A., Banas, J. A., Jelley-Gibbs, D. M., Walsh, M. C., Preissler, M. T., Gosselin, E. J.
(2001). Lipoteichoic Acid Inhibits Interleukin-2 (IL-2) Function by Direct Binding to IL-2. CVI
8: 972-979
[Abstract]
[Full Text]
-
Levy, O.
(2000). Antimicrobial proteins and peptides of blood: templates for novel antimicrobial agents. Blood
96: 2664-2672
[Abstract]
[Full Text]
-
Friedrich, C. L., Moyles, D., Beveridge, T. J., Hancock, R. E. W.
(2000). Antibacterial Action of Structurally Diverse Cationic Peptides on Gram-Positive Bacteria. Antimicrob. Agents Chemother.
44: 2086-2092
[Abstract]
[Full Text]
-
Hancock, R. E. W., Scott, M. G.
(2000). The role of antimicrobial peptides in animal defenses. Proc. Natl. Acad. Sci. USA
97: 8856-8861
[Abstract]
[Full Text]
-
Friedrich, C. L., Rozek, A., Patrzykat, A., Hancock, R. E. W.
(2001). Structure and Mechanism of Action of an Indolicidin Peptide Derivative with Improved Activity against Gram-positive Bacteria. J. Biol. Chem.
276: 24015-24022
[Abstract]
[Full Text]